Related Experiment Video
Updated: May 12, 2026
08:07
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
Published on: April 12, 2019
Decoding the Hexosamine Biosynthesis Pathway: Implications for Novel Therapeutic Strategies in Sarcoma
Pegah Rahimizadeh1,2, Richard Miallot2,3, Chelsea De Bellis1,2
1Division of Surgical and Interventional Sciences, McGill University, Montreal, Canada.
Journal of Cellular Physiology
|May 11, 2026
Summary
The hexosamine biosynthesis pathway (HBP) fuels cancer growth by altering protein glycosylation. Inhibiting HBP offers a promising therapeutic strategy for sarcoma by targeting cancer cell metabolism.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Cancer cells exhibit altered metabolism to support rapid proliferation.
- The hexosamine biosynthesis pathway (HBP) acts as a nutrient sensor, producing UDP-GlcNAc.
- UDP-GlcNAc is crucial for post-translational modifications like glycosylation, impacting protein function and malignancy.
Purpose of the Study:
- To review molecular alterations and prognostic significance of HBP enzymes in sarcoma.
- To identify glycosylation sites on sarcoma drivers and their functional impact.
- To explore HBP inhibition as a potential therapeutic strategy for sarcoma.
Main Methods:
- Literature review of HBP alterations in sarcoma.
- Analysis of glycosylation in mesenchymal tumor drivers.
- Summary of preclinical studies on HBP inhibitors in cancer models.
Main Results:
- HBP enzyme expression and alterations in sarcoma are linked to prognosis.
- Specific glycosylation patterns on sarcoma oncoproteins influence their function.
- HBP inhibitors show potential in preclinical sarcoma models.
Conclusions:
- Targeting the HBP represents a novel therapeutic avenue for sarcoma.
- Further research and technological advancements are needed for HBP inhibitor development.
- Understanding HBP's role in sarcoma can guide future drug discovery efforts.
